Abstract
We investigated the biomarker signatures of two previously reported phenotypical prefrailty (PF) types in the first wave of The Irish Longitudinal Study on Ageing (TILDA): PF1 (unexplained weight loss and/or exhaustion) and PF2 (one or two among slowness, weakness, and low physical activity). Binary logistic regression models evaluated the independent associations between available plasma biomarkers and each PF type (compared to robust and compared to each other), while adjusting for age, sex, and education. A total of 5307 participants were included (median age 61 years, 53% women) of which 1473 (28%) were prefrail (469 PF1; 1004 PF2), 171 were frail, and 3663 were robust. The PF2 median age was eight years older than the PF1 median age. Higher levels of lutein and zeaxanthin were independently associated with the lower likelihood of PF1 (OR: 0.77, p < 0.001 and OR: 0.81, p < 0.001, respectively). Higher cystatin C was associated with PF1 (OR: 1.23, p = 0.001). CRP (OR: 1.19, p < 0.001), cystatin C (OR: 1.36, p < 0.001), and HbA1c (OR: 1.18, p < 0.001) were independently associated with PF2, while a higher total (OR: 0.89, p = 0.004) and HDL (OR: 0.87, p < 0.001) cholesterol seemed to be PF2-protective. While PF1 seemed to be inversely associated with serum carotenoid concentrations and hence has an oxidative signature, PF2 seemed to have pro-inflammatory, hyperglycemic, and hypolipidemic signatures. Both PF types were associated with higher cystatin C (lower kidney function), but no biomarkers significantly distinguished PF1 vs. PF2. Further research should elucidate whether therapies for different PF types may require targeting of different biological pathways.
Highlights
A previous study based on The Irish Longitudinal Study on Ageing (TILDA) suggested that the PF stage of the frailty phenotype (FP) can be divided into two subtypes with different longitudinal disability trajectories and mortality risks: a lower risk prefrail 11 (PF1) and a higher risk PF2 [6]
To investigate biological differences between the two PF subtypes, we examined available plasma biomarkers in TILDA, many of which are routinely utilized in the diagnosis and/or management of several age-related chronic diseases, which may be associated with the development of frailty
While PF1 seemed to be inversely associated with serum carotenoid concentrations and have an oxidative signature, PF2 seemed to have pro-inflammatory, hyperglycemic, and hypolipidemic signatures
Summary
Frailty is an important concept in geriatrics that is increasingly guiding clinical decision-making and tailored therapeutic interventions for older patients [1]. While several operational definitions of frailty have been proposed, one of the most widely used is the physical frailty phenotype (FP) as defined by Fried et al [2,3] This includes a potentially more reversible prefrailty (PF) stage that has attracted much interest due to its greater potential for preventative and health promotion strategies; it has been argued that PF may be heterogeneous [4,5]. To investigate biological differences between the two PF subtypes, we examined available plasma biomarkers in TILDA, many of which are routinely utilized in the diagnosis and/or management of several age-related chronic diseases, which may be associated with the development of frailty. We examined two dietary carotenoid biomarkers, lutein and zeaxanthin These are important for macular pigmentation and low levels are linked to the development of age-related macular degeneration (AMD) [11]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.